Skip to main content
. Author manuscript; available in PMC: 2014 Mar 1.
Published in final edited form as: Hepatology. 2013 Feb 15;57(3):1098–1106. doi: 10.1002/hep.26146

Figure 1. Development of liver cancer in FXR/SHP KO mice involves activation of gankyrin and elimination of C/EBPα.

Figure 1

A. Liver tumors in 17-month-old FXR/SHP KO mice. B. A representative picture of BrdU staining of livers of WT and FXR/SHP KO mice. Arrows show BrdU positive hepatocytes. Bar graphs show a summary of BrdU staining for two animals. C. Expression of gankyrin is elevated in liver cancer samples from FXR/SHP KO mice. Western blotting was performed with antibodies to proteins shown on the right. Dark and light exposures are shown for cyclin D3. CRM; cross reactive protein and β-actin show protein loading. D. Levels of gankyrin and C/EBPα mRNA in livers of 17-month-old mice. E. Expression of gankyrin and C/EBPα in 6-month-old FXR/SHP KO mice. Liver proteins of WT and FXR/SHP KO mice were examined by Western blotting with Abs to FXR, gankyrin, cdk4, C/EBPα and with Abs to ph-S193 isoform of C/EBPα. Each membrane was reprobed with β-actin. F. Levels of gankyrin and C/EBPα are shown as a summary of three independent experiments.